Makker, V., Filiaci, V. L., Chen, L., Darus, C. J., Kendrick, J. E., Sutton, G., . . . Aghajanian, C. (2015). Phase II Evaluation of Dalantercept, a Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK1) Receptor Fusion Protein, for the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N. Gynecol Oncol.

Makker, Vicky, Virginia L. Filiaci, Lee-may Chen, Christopher J. Darus, James E. Kendrick, Gregory Sutton, Katherine Moxley, et Carol Aghajanian. "Phase II Evaluation of Dalantercept, a Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK1) Receptor Fusion Protein, for the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N." Gynecol Oncol 2015.

Makker, Vicky, et al. "Phase II Evaluation of Dalantercept, a Soluble Recombinant Activin Receptor-Like Kinase 1 (ALK1) Receptor Fusion Protein, for the Treatment of Recurrent or Persistent Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study 0229N." Gynecol Oncol 2015.